BIOA News

BioAge Labs, Partner von HitGen, verabreicht erste Dosis an Teilnehmer der Phase-2-Studie zu BGE-102, einem neuartigen oralen NLRP3-Inhibitor zur Senkung des kardiovaskulären Risikos

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

Form 8-K

Number of shares and votes in BioArctic AB (publ) as of May 29, 2026

Bulletin from the Annual General Meeting in BioArctic AB (publ) USA - English USA - English

BioAge Labs to Present at Upcoming Investor Conferences

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach

Form 8-K